PL190615B1 - Kompozycja szczepionki dla świń, zastosowanie kompozycji szczepionki, zestaw do szczepienia, szczepionka dla świń i zastosowanie plazmidu - Google Patents

Kompozycja szczepionki dla świń, zastosowanie kompozycji szczepionki, zestaw do szczepienia, szczepionka dla świń i zastosowanie plazmidu

Info

Publication number
PL190615B1
PL190615B1 PL97331249A PL33124997A PL190615B1 PL 190615 B1 PL190615 B1 PL 190615B1 PL 97331249 A PL97331249 A PL 97331249A PL 33124997 A PL33124997 A PL 33124997A PL 190615 B1 PL190615 B1 PL 190615B1
Authority
PL
Poland
Prior art keywords
vaccine
gene
plasmid
virus
swine
Prior art date
Application number
PL97331249A
Other languages
English (en)
Polish (pl)
Other versions
PL331249A1 (en
Inventor
Jean-Christophe Audonnet
Annabelle Bouchardon
Philippe Baudu
Michel Riviere
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Publication of PL331249A1 publication Critical patent/PL331249A1/xx
Publication of PL190615B1 publication Critical patent/PL190615B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/107Vibrio
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/23Parvoviridae, e.g. feline panleukopenia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14311Parvovirus, e.g. minute virus of mice
    • C12N2750/14322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14311Parvovirus, e.g. minute virus of mice
    • C12N2750/14334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/10011Arteriviridae
    • C12N2770/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/815Viral vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL97331249A 1996-07-19 1997-07-15 Kompozycja szczepionki dla świń, zastosowanie kompozycji szczepionki, zestaw do szczepienia, szczepionka dla świń i zastosowanie plazmidu PL190615B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609338A FR2751224B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
PCT/FR1997/001313 WO1998003658A1 (fr) 1996-07-19 1997-07-15 Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs

Publications (2)

Publication Number Publication Date
PL331249A1 PL331249A1 (en) 1999-07-05
PL190615B1 true PL190615B1 (pl) 2005-12-30

Family

ID=9494450

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97331249A PL190615B1 (pl) 1996-07-19 1997-07-15 Kompozycja szczepionki dla świń, zastosowanie kompozycji szczepionki, zestaw do szczepienia, szczepionka dla świń i zastosowanie plazmidu

Country Status (20)

Country Link
US (2) US6207165B1 (https=)
EP (1) EP0912743B1 (https=)
JP (1) JP2001500111A (https=)
KR (1) KR100496249B1 (https=)
CN (2) CN101121023A (https=)
AR (1) AR007864A1 (https=)
AU (1) AU735291B2 (https=)
BR (1) BR9710740A (https=)
CA (1) CA2261346C (https=)
CO (1) CO4750676A1 (https=)
DE (1) DE69734284T2 (https=)
DK (1) DK0912743T3 (https=)
ES (1) ES2251030T3 (https=)
FR (1) FR2751224B1 (https=)
HU (1) HUP9903822A3 (https=)
PL (1) PL190615B1 (https=)
RU (1) RU2305559C2 (https=)
TW (1) TW589190B (https=)
UA (2) UA91675C2 (https=)
WO (1) WO1998003658A1 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762901B2 (en) * 1996-07-19 2003-07-10 Merial Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases
CA2223029A1 (en) * 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
EP0863151A1 (en) * 1997-02-12 1998-09-09 Akzo Nobel N.V. "Canine parvovirus dna vaccines"
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US7192594B2 (en) 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
FR2776294B1 (fr) * 1998-03-20 2001-06-22 Merial Sas Nouveaux circovirus porcins ; vaccins et reactifs de diagnostic
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
DE69837934T2 (de) * 1997-12-11 2008-02-21 University Of Saskatchewan, Saskatoon Multisystemisches kümmerwuchssyndrom durch viren in schweinen
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
KR20030054139A (ko) * 2001-12-24 2003-07-02 학교법인 건국대학교 돼지 오제스키병 바이러스의 gD 유전자를 포함하는재조합 발현 벡터 및 이를 이용한 DNA 백신
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
US7527967B2 (en) * 2003-11-25 2009-05-05 Academia Sinica Recombinant baculovirus and virus-like particle
MXPA06009452A (es) 2004-02-19 2007-03-15 Univ Alberta Polimorfismos del promotor de leptin y sus usos.
PT1881845E (pt) 2005-04-25 2010-05-31 Merial Ltd Vacinas de vírus nipah
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP3147296A1 (en) 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
RU2559527C2 (ru) 2008-11-28 2015-08-10 Мериал Лимитед Рекомбинантная вакцина от птичьего гриппа и её применение
WO2010115133A2 (en) 2009-04-03 2010-10-07 Merial Limited Newcastle disease virus vectored avian vaccines
CN103260643A (zh) 2009-12-28 2013-08-21 梅里亚有限公司 重组ndv抗原及其用途
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
ES2617743T3 (es) 2010-03-12 2017-06-19 Merial, Inc. Vacunas recombinantes del virus de la lengua azul y sus utilizaciones
CN102373181B (zh) * 2010-08-09 2014-06-11 中山大学 猪流感病毒和猪蓝耳病病毒混合病毒样颗粒、制备方法和应用
CN102370976B (zh) * 2010-08-09 2014-06-11 中山大学 猪流感病毒和猪口蹄疫病毒的混合病毒样颗粒、制备方法和应用
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
HK1200329A1 (en) 2011-04-25 2015-08-07 先进生物学实验室股份有限公司 Truncated hiv envelope proteins (env), methods and compositions related thereto
WO2012153160A1 (es) 2011-05-07 2012-11-15 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra prrs en vector viral
BR112013030321A2 (pt) * 2011-05-27 2017-07-11 Sinovet Beijing Biotechnology Co Ltd composição de vacina, método para preparar a composição de vacina, uso da composição de vacina, método para imunizar um porco, cepa de vacina contra csfv e uso de uma célula no cultivo de uma cepa de vacina contra csfv.
ES2764079T3 (es) 2011-05-27 2020-06-02 Boehringer Ingelheim Animal Health Usa Inc Vacunas genéticas contra el virus Hendra y el virus Nipah
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
SI2741740T1 (sl) 2011-08-12 2017-08-31 Merial, Inc. Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
ES2632429T3 (es) 2012-02-14 2017-09-13 Merial, Inc. Vacunas subunitarias de rotavirus y procedimientos para la fabricación y utilización de las mismas
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
ES2664069T3 (es) 2012-06-13 2018-04-18 Merial, Inc. Vacunas contra BTV y AHSV de genoma reordenado
CN102807989B (zh) * 2012-08-01 2014-04-23 中国人民解放军军事医学科学院军事兽医研究所 犬科和/或猫科动物疫病重组活载体疫苗的制备方法
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
JP6236144B2 (ja) * 2013-05-31 2017-11-22 普莱柯生物工程股▲ふん▼有限公司 豚ヘルペスウイルス、ワクチン組成物及びその製造方法と応用
CN105579060B (zh) 2013-09-25 2021-03-16 硕腾服务有限责任公司 Pcv2b趋异株疫苗组合物以及使用方法
CN104248757B (zh) * 2014-09-30 2017-10-27 普莱柯生物工程股份有限公司 猪伪狂犬病病毒疫苗组合物及其制备方法和应用
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
DK3313864T3 (da) 2015-06-23 2021-11-01 Boehringer Ingelheim Animal Health Usa Inc Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf
CN105693827B (zh) * 2015-06-29 2020-05-15 普莱柯生物工程股份有限公司 一种猪伪狂犬病病毒亚单位疫苗及其制备方法和应用
CN104998256A (zh) * 2015-07-14 2015-10-28 天津瑞普生物技术股份有限公司 一种猪用三联灭活疫苗的制备方法
WO2017031120A1 (en) 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof
FI3355915T3 (fi) 2015-09-29 2024-01-12 Boehringer Ingelheim Animal Health Usa Inc Koirien parvoviruksen (CPV) viruksen kaltaisten hiukkasten (VLP) rokotteet ja niiden käytöt
MA42640B1 (fr) 2015-11-23 2021-06-30 Merial Inc Protéines de fusion de dmdv et e2 et leurs utilisations
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8901651A (nl) * 1989-06-29 1991-01-16 Centraal Diergeneeskundig Inst Vaccin tegen pestivirusinfecties, zoals varkenspest; daarvoor bruikbare nucleotidesequenties en polypeptiden.
US6592873B1 (en) * 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
HU218430B (hu) * 1993-02-08 2000-08-28 Bayer Corp. Eljárás sertés reproduktív és légzési szindróma vírus (PRRSV) tenyésztésére és annak alkalmazása vakcinában
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5516905A (en) * 1994-08-30 1996-05-14 University Of Massachusetts Medical Center Antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
CA2216308A1 (en) * 1995-12-21 1997-07-03 Solvay (Societe Anonyme) Plasmid vaccine for pseudorabies virus

Also Published As

Publication number Publication date
CO4750676A1 (es) 1999-03-31
WO1998003658A1 (fr) 1998-01-29
CN1225684A (zh) 1999-08-11
DE69734284T2 (de) 2006-07-13
TW589190B (en) 2004-06-01
RU2002133052A (ru) 2005-01-20
KR100496249B1 (ko) 2006-01-27
HUP9903822A3 (en) 2010-01-28
US6207165B1 (en) 2001-03-27
AU735291B2 (en) 2001-07-05
CN1329513C (zh) 2007-08-01
US6576243B1 (en) 2003-06-10
EP0912743A1 (fr) 1999-05-06
CA2261346A1 (en) 1998-01-29
DE69734284D1 (de) 2006-02-09
ES2251030T3 (es) 2006-04-16
UA77935C2 (uk) 2007-02-15
FR2751224B1 (fr) 1998-11-20
KR20000065256A (ko) 2000-11-06
HUP9903822A2 (hu) 2000-03-28
RU2305559C2 (ru) 2007-09-10
CN101121023A (zh) 2008-02-13
AU3699197A (en) 1998-02-10
FR2751224A1 (fr) 1998-01-23
JP2001500111A (ja) 2001-01-09
UA91675C2 (ru) 2010-08-25
EP0912743B1 (fr) 2005-09-28
CA2261346C (en) 2012-01-03
BR9710740A (pt) 1999-08-17
PL331249A1 (en) 1999-07-05
AR007864A1 (es) 1999-11-24
DK0912743T3 (da) 2006-01-30

Similar Documents

Publication Publication Date Title
PL190615B1 (pl) Kompozycja szczepionki dla świń, zastosowanie kompozycji szczepionki, zestaw do szczepienia, szczepionka dla świń i zastosowanie plazmidu
US6228846B1 (en) Polynucleotide vaccine formula against canine pathologies
US6376473B1 (en) Polynucleotide vaccine formula in particular against bovine respiratory pathology
PL188409B1 (pl) Szczepionki do leczenia koni, zastosowanie plazmidu do wytwarzania szczepionki i zestaw do szczepienia koni
HU224833B1 (en) Intradermal bovine polynucleotide vaccine
JP2004313196A (ja) コロナウイルスに対するワクチン接種用組成物および方法
PL194348B1 (pl) Szczepionki DNA i zastosowanie polimerów kwasu akrylowego albo metakrylowego oraz kopolimerów bezwodnika maleinowego i pochodnej alkenylowej oraz zastosowanie karbopolu
AU762901B2 (en) Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases
TWI912376B (zh) 減毒之豬流行性下痢病毒
US7294338B2 (en) Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
AU776827B2 (en) Polynucleotide vaccine formula, particularly for treating bovine respiratory disease
NZ506427A (en) A canidae vaccine comprising the rabies G gene under the control of the CMV-IE promoter